Latest Immunomedics (IMMU) Headlines SHAREHOLDE
Post# of 51
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces Class Action Involving IMMUNOMEDICS, INC. and Its Board of Directors and a Deadline of April 28, 2014 to Seek a Lead Plaintiff Position -- IMMU
PR Newswire - Tue Mar 11, 1:36PM CDT
Levi & Korsinsky announces that a class action lawsuit has been commenced in the USDC for the District of New Jersey on behalf of investors who purchased Immunomedics, Inc. ("Immunomedics" or the "Company") (Nasdaq: IMMU) common stock between May 9, 2013 and October 9, 2013.
The Rosen Law Firm Announces Class Action Charging Securities Violations Against Immunomedics, Inc. -- IMMU
GlobeNewswire - Tue Mar 11, 12:19PM CDT
The Rosen Law Firm, P.A. today announced that a class action lawsuit has been filed on behalf of purchasers of the common stock of Immunomedics, Inc. (Nasdaq:IMMU) between May 9, 2013 and October 9, 2013.
Attention Immunomedics, Inc. Investors: Immunomedics Misled Investors According to a Recently Filed Class Action
PR Newswire - Thu Mar 06, 4:24PM CST
Shareholder rights law firm Robbins Arroyo LLP announces that an investor of Immunomedics, Inc. (NASDAQ: IMMU) has filed a federal securities fraud class action complaint in the U.S. District Court for the District of New Jersey. The complaint alleges that the company and certain of its officers and directors violated the Securities and Exchange Act of 1934 between May 9, 2013 and October 9, 2013 (the "Class Period"). Immunomedics is a biopharmaceutical company which focuses on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune, and other serious diseases.